Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy